모구형질세포양수지세포종양 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 최종 용도별, 부문별 예측(2024-2030년)

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Stem Cell Transplantation), By End Use (Hospitals, Specialty Clinics), And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,828,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,311,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,279,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

모구형질세포양수지세포종양 시장의 성장과 동향 :

Grand View Research의 최신 리포트에 따르면 세계의 모구형질세포양수지세포종양 시장 규모는 2030년까지 2억 1,427만 달러에 달할 것으로 예측되며, 2024-2030년 CAGR은 7.7%로 성장할 것으로 예측됩니다.

이 시장에는 이 희귀 혈액 악성 종양의 진단, 치료 및 관리에 필수적인 다양한 요소들이 포함되어 있습니다.

BPDCN의 발병률은 진단 방법의 개선과 의료진과 환자들의 인식이 높아짐에 따라 증가 추세에 있습니다. BPDCN의 분자 및 유전적 측면에 대한 이해가 크게 진전됨에 따라 표적 치료법이 개발되고 있으며, 유망한 약물이 임상시험 중에 있습니다.

BPDCN은 여러 지역에서 희귀질환으로 분류되어 시장 독점권 연장, 세액공제 등의 혜택으로 의약품에 대한 투자를 촉진하고 있습니다. 맞춤형 의료로의 전환으로 유전자 프로파일에 기반한 치료 전략이 강화되면서 맞춤형 치료 시장이 확대되고 있습니다.

모구형질세포양수지세포종양 시장 보고서 하이라이트

• 치료별로는 화학요법이 2023년 38.7%의 최대 매출 점유율로 시장을 장악할 것으로 예상됩니다. 화학요법과 tagraxofusp와 같은 새로운 약물의 조합은 BPDCN 치료를 변화시킬 것입니다. 이는 화학요법의 매우 중요한 역할을 강조하며, 치료 결과의 개선과 표적 치료의 도입을 통해 시장 성장을 가속할 것입니다.
• 최종 사용처 기준, 병원이 2023년 57.5%의 최대 매출 점유율로 시장을 장악할 것으로 예상됩니다. 미국과 유럽에서 연간 1,000-1,400건으로 추정되는 BPDCN 발병률이 증가함에 따라 병원 방문이 증가하고 있습니다. 첨단 진단 툴와 종양학과의 전문화 덕분에 효과적인 치료 시작에 필수적인 적시에 정확한 진단이 용이해졌습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 모구형질세포양수지세포종양 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 모구형질세포양수지세포종양 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 모구형질세포양수지세포종양 시장 : 치료별 추정·동향 분석

• 세계의 모구형질세포양수지세포종양 시장 : 치료별 대시보드
• 세계의 모구형질세포양수지세포종양 시장 : 치료별 변동 분석
• 치료별 매출
• 화학요법
• 면역치료
• 줄기세포 이식
• 표적치료
• 기타

제5장 모구형질세포양수지세포종양 시장 : 최종 용도별 추정·동향 분석

• 세계의 모구형질세포양수지세포종양 시장 : 최종 용도별 대시보드
• 세계의 모구형질세포양수지세포종양 시장 : 최종 용도별 변동 분석
• 최종 용도별 매출
• 병원
• 전문 클리닉
• 기타

제6장 모구형질세포양수지세포종양 시장 : 치료 및 최종 용도별 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 기업/경쟁의 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • 주요 기업의 시장 점유율 분석, 2023년
  • AbbVie Inc.
  • ImmunoGen, Inc.
  • Mustang Bio
  • Genentech, Inc.
  • Stemline Therapeutics, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Cellex Patient Treatment GmbH
  • Xencor
  • Resverlogix

KSA

영문 목차

영문목차

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Growth & Trends:

The global blastic plasmacytoid dendritic cell neoplasm market size is anticipated to reach USD 214.27 million by 2030 and is projected to grow at a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of elements critical to diagnosing, treating, and managing this rare hematological malignancy.

The incidence of BPDCN is increasing, attributed to better diagnostic methods and heightened awareness among healthcare providers and patients. This rise in incidence boosts the demand for effective treatments. Significant advancements in understanding BPDCN's molecular and genetic aspects led to the development of targeted therapies, with promising drugs undergoing clinical trials.

BPDCN is classified as an orphan disease in various regions, encouraging pharmaceutical investment through incentives such as extended market exclusivity and tax credits. The shift towards personalized medicine enhances treatment strategies based on genetic profiles, expanding the market for customized therapies.

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Report Highlights:

• Based on treatment, Chemotherapy dominated the market with the largest revenue share of 38.7% in 2023. Combining chemotherapy with novel agents such as tagraxofusp transforms BPDCN treatment. This highlights chemotherapy's pivotal role and drives market growth through improved outcomes and the introduction of targeted therapies.
• Based on end use, hospitals dominated the market with the largest revenue share of 57.5% in 2023. The rising incidence of BPDCN, estimated at 1,000 to 1,400 cases annually in the U.S. and Europe, increased hospital visits. Advanced diagnostic tools and specialized oncology departments facilitate timely and accurate diagnoses essential for effective treatment initiation.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence rates of BPDCN
    • 3.2.1.2. Advancements in treatment options
    • 3.2.1.3. Growing awareness and diagnosis of rare hematological malignancies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited treatment option
    • 3.2.2.2. Challenges in diagnosis
• 3.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Estimates & Trend Analysis

• 4.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Dashboard
• 4.2. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Movement Analysis
• 4.3. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market by Treatment, Revenue
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Immunotherapy
  • 4.5.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Stem Cell Transplantation
  • 4.6.1. Stem cell transplantation market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Targeted Therapy
  • 4.7.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Other
  • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Estimates & Trend Analysis

• 5.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Dashboard
• 5.2. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Movement Analysis
• 5.3. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Regional Estimates & Trend Analysis by Treatments, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. AbbVie Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. ImmunoGen, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Mustang Bio
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Genentech, Inc.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Stemline Therapeutics, Inc.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Jazz Pharmaceuticals, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Cellex Patient Treatment GmbH
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Xencor
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Resverlogix
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives

관련자료